Engineered immune cells take on advanced cancers in early trial

This study tests a new treatment called MSLN CAR-T for people with advanced solid tumors that have not responded to standard care. The therapy uses a patient's own immune cells, modified in a lab to target a protein called MSLN found on tumor cells. Up to 20 adults will receive chemotherapy before the cell infusion to help the cells work better. The main goal is to see if the treatment is safe and to get an early look at whether it can shrink tumors.